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Pulmonary embolismAbstract Background: Diagnosis of pulmonary embolism (PE) in early stages by conventional
laboratory methods is difﬁcult because the currently available tests lack sufﬁcient sensitivity and
speciﬁcity. Hepatocyte growth factor (HGF) was originally regarded as speciﬁc to hepatocytes,
but has been found to be identical to the scatter factor affecting a wide range of tissues including
the lungs.
The aim of this work is to study the relationship between HGF and PE.
Patients and methods: This study included 40 patients with PE, 40 stable angina (SA) patients,
and 10 healthy controls. HGF and D-dimer were measured in all patients of this study.
Results: Mean HGF was signiﬁcantly higher in the PE group (788.8 ± 361.5 pg/ml) compared
to the SA group (262.4 ± 158.1 pg/ml) and control group (215.5 ± 18.5 pg/ml) (P= 0.0001).
The predictive values of D-dimer in the diagnosis of PE were as follows: 100% sensitivity and neg-
ative predictive value, 80% speciﬁcity, 83.3% positive predictive value and 90% accuracy, while
those of HGF were: 97.5% sensitivity, 97.4% negative predictive value, 92.5% speciﬁcity, 92.9%
positive predictive value and 95% accuracy. When used both D-dimer and HGF together the values
improved to: 100% sensitivity and negative predictive value, 97.5% speciﬁcity, 97.6% positive
predictive value and 98.8% accuracy.
690 A. Dawood et al.Conclusions: Our observations suggest that the plasma HGF level may be a useful biological
marker of pulmonary ischemia, and a valuable tool for early diagnosis of PE. Clariﬁcation of
the mechanisms, characteristics, and biological signiﬁcance of HGF elevation is important for clin-
ical use in diagnosing and treating pulmonary ischemia. The use of both D-dimer and HGF
increases the predictive power of both tests when used together. The clinical signiﬁcance of the role
of HGF in PE opens a new therapeutic area in treating acute ischemic pulmonary disease that
would be able to prolong the time frame for the application of reperfusion–thrombolytic therapy.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
Pulmonary embolism (PE) is a common and often fatal post-
operative complication. Late diagnosis and delayed manage-
ment of this condition are associated with pulmonary
infarction. The common clinical manifestations in pulmonary
embolisms are frequently inconsistent and often vague. Rou-
tine laboratory examinations are also nonspeciﬁc. A chest ﬁlm,
arterial saturation, and electrocardiogram may be helpful in
excluding other cardiorespiratory diseases, but are frequently
unreliable in establishing an objective diagnosis of pulmonary
embolism. Although pulmonary arteriography is the gold stan-
dard for the diagnosis of pulmonary embolism, it requires
expensive equipment and trained radiologists, and the patient
could show sensitivity to the contrast agents used. Therefore, it
is necessary to use a more convenient and reliable method of
diagnosing pulmonary embolism [1].
Hepatocyte growth factor (HGF) was initially thought to
be liver-speciﬁc, but it has become clear that HGF acts on a
variety of epithelial cells and organs such as mitogen, motogen
and morphogen [2,3]. HGF may also be involved in vascular
proliferation and regeneration, as it is a principal mediator
of mesenchymal, epithelial, and endothelial interactions that
contribute to wound healing and angiogenesis. It is likely that
HGF plays an important role in ischemic lung injury [4].
It is unclear whether high HGF levels are a risk factor for
ischemic pulmonary disease or a result of it. To address these
issues, we conducted this study to evaluate the association be-
tween circulating HGF levels and pulmonary embolism and
whether it could serve as an indicator of this disease in the
early period of pulmonary ischemia.Patients & methods
This study included 40 patients with pulmonary embolism (PE
group 1), 40 stable angina patients (SA group 2), and 10
healthy controls (group 3).
All patients and controls were recruited from patients
attending Intensive care unit, Menouﬁya University Hospital,
Shebin El-Kom and Critical Care Unit, Alexandria University
Hospital. All studied subjects underwent a detailed clinical his-
tory and physical examination. An informed consent was ob-
tained from all subjects enrolled in the study. This study was
approved by our Ethics Committee of Faculty of Medicine.
Exclusion criteria were patients whose medical history was
consistent with systemic metabolic disorders (other than DM),
systemic vasculitis, or apparent liver disease.The control group consists of 10 examinees of the same age
and sex.
Laboratory assessment:
1- Liver enzymes (SGOT, SGPT) were done on autoanaly-
ser SYNCHRON CX5 from Beckman.
2- Lipid proﬁle.
3- D-Dimer: was considered positive if >500 ng/ml FEU
(ﬁbrinogen expressed unit by using latex agglutination
test).
4- Hepatocyte growth factor (HGF) was measured in all
patients and controls within 24 h of onset of pulmonary
embolism and before giving heparin. HGF is relatively
stable and that a single measurement at baseline may
reﬂect an individual’s long-term exposure to this growth
factor. It was estimated by ELISA kit based on standard
sandwich enzyme-linked immune-sorbent assay pro-
vided by biorbyt. We did not research the time course
of HGF concentration in patients with pulmonary
thromboembolism who received heparin treatment for
3–7 days after the admission, because Matsumori et al.
found that serum HGF concentration increased immedi-
ately after heparin use [5].
Pulmonary embolisms were diagnosed by using computed
tomography pulmonary angiography.Statistical analysis
Data input to the computer was done followed by tabulation
and analysis. Analysis was done using SPSS-9 (Statistical
Package for Social Sciences version 12). We represent the data
in arithmetic mean, standard deviation, frequency and percent-
age. The following tests were used to analyze the results: anal-
ysis of variance (ANOVA), least signiﬁcant difference, Student
‘‘t’’ test, Chi square test and correlation coefﬁcient test. Statis-
tical analysis was done at level of signiﬁcance of P 6 0.05.Results
There were no signiﬁcant differences between the 3 studied
groups as regards age, gender and body mass index (Table 1).
There were no signiﬁcant differences between both patient
groups as regards systolic and diastolic blood pressure
(P= 0.321 and =0.167, respectively).
There were no signiﬁcant differences between the PE group
and SA group as regards liver enzymes (ALT, AST), renal
Table 1 Comparison among the studied groups as regards
demographic data.
PE group
(n= 40)
SA group
(n= 40)
Control group
(n= 10)
F-test
Age (years)
Mean ± SD 62.5 ± 9.3 63.8 ± 7.7 61.2 ± 7.1 P= 0.192NS
Sex
Males 22 (55.0%) 20 (50.0%) 5 (50.0%) X2 = 0.895
Females 18 (45.0%) 20 (50.0%) 5 (50.0%) P= 0.223NS
Body mass index (kg/m2)
Mean ± SD 27.4 ± 5.12 27.3 ± 4.7 26.9 ± 3.8 P= 0.215NS
PE group, pulmonary embolism group; SA group, stable angina
group; n, number; NS, non-signiﬁcant.
Table 2 Comparison among the studied groups as regards
laboratory investigations.
PE group
(n= 40)
SA group
(n= 40)
t-Test
AST (U/L)
Mean ± SD 25.5 ± 12.3 27.8 ± 11.9 P= 0.571NS
ALT (U/L)
Mean ± SD 22.5 ± 13.4 23.9 ± 11.5 P= 0.356NS
Blood urea (mg/dl)
Mean ± SD 41.5 ± 10.7 37.0 ± 7.4 P= 0.915NS
Serum creatinine
(mg/dl)
Mean ± SD 1.03 ± 0.2 1.02 ± 0.3 P= 0.176NS
Serum cholesterol
(mg/dl)
Mean ± SD 241.6 ± 43.5 231.9 ± 44.1 P= 0.091NS
Serum triglycerides
(mg/dl)
Mean ± SD 171.4 ± 56.6 169.9 ± 53.8 P= 0.211NS
Serum LDL (mg/dl)
Mean ± SD 173.9 ± 39.1 170.6 ± 41.7 P= 0.331NS
Serum HDL (mg/dl)
Mean ± SD 39.1 ± 9.2 41.7 ± 14.1 P= 0.156NS
Serum D-dimer (ng/ml) Chi-square test
>500 ng/ml n= 40 n= 9 P= 0.0001*
PE group, pulmonary embolism group; SA group, stable angina
group; n, number;NS, non-signiﬁcant; AST, aspartate transaminase;
ALT, alanine transaminase; LDL, low density lipoprotein; HDL,
high density lipoprotein.
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serum triglycerides, high density lipoprotein cholesterol, and
serum low density lipoprotein cholesterol. The number ofTable 3 Comparison among the studied groups as regards hepatoc
PE group
(n= 40)
SA group
(n= 40)
Hepatocyte growth factor (pg/ml)
Mean ± SD 788.8 ± 361.5 262.4 ± 158.1
PE group, pulmonary embolism group, SA Group, stable angina group;
* Signiﬁcant (P< 0.05).patients with positive D-dimer (>500 ng/ml) was signiﬁcantly
higher in the PE group compared to the SA group (Table 2).
The mean hepatocyte growth factor was signiﬁcantly higher
in the PE group (788.8 ± 361.5 pg/ml) compared to the SA
group (262.4 ± 298.1 pg/ml) and group 3 (215.5 ± 18.5 pg/
ml) (P= 0.0001) (Table 3).
The predictive values of D-dimer in the diagnosis of PE were
as follows: 100% sensitivity and negative predictive value,
80% speciﬁcity, 83.3% positive predictive value and 90%
accuracy, while those of HGF were: 97.5% sensitivity,
97.4% negative predictive value, 92.5% speciﬁcity, 92.9% po-
sitive predictive value and 95% accuracy. When used both D-
dimer and HGF together the values improved to: 100% sensi-
tivity and negative predictive value, 97.5% speciﬁcity, 97.6%
positive predictive value and 98.8% accuracy (Table 4).
Discussion
HGF is a mesenchymal-derived pleiotropic factor that regu-
lates growth, motility, and morphogenesis of various cells.
Although HGF was known initially as a potent mitogen for
hepatocytes, it has recently been shown to have effects on
other cells, including epithelial and endothelial cells. It is ex-
pressed in several tissues including lung, kidney, heart and
brain [6].
In lung regeneration, several polypeptide growth factors,
such as endothelial growth factor (EGF), insulin like growth
factor-I (IGF-I), and hepatocyte growth factor (HGF) were re-
ported to elicit mitogenic activity for alveolar type II epithelial
cells and bronchial epithelial cells [7]. Compensatory prolifer-
ation and subsequent differentiation of alveolar type II epithe-
lial cells and bronchial epithelial cells are essential for lung
regeneration. In case of alveolar injury, alveolar type I epithe-
lial cells are predominantly damaged, and alveolar type II cells
proliferate and differentiate into alveolar type I epithelial cells.
In case of bronchial injury, the remaining bronchial epithelial
cells, Clara cells, and basal cells are thought to proliferate and
differentiate into multipotent progenitor cells, and bronchial
epithelial cells are regenerated by the differentiation of those
cells [8–10].
Several studies have demonstrated that human HGF may
play a role in endothelial cell growth, arterial vascularization,
pathogenesis of coronary artery diseases, and cerebral infarc-
tion. Endothelial dysfunction and thrombosis play an impor-
tant role in cardiovascular diseases including acute coronary
syndromes, pulmonary embolism, and acute aortic dissection
[11–15]. Gordon et al. [16] and Ueda et al. [17] reported the
presence of HGF in coronary artery plaques and thrombi.
Matsumori et al. [13] found that increased HGF had relation-
ship with thrombotic diseases.yte growth factor.
Control group
(n= 20)
F-test LSD
215.5 ± 18.5 P= 0.0001* Group I vs II, III
n, number.
Table 4 Comparison between serum HGF and D-dimer as regards the predictive power of diagnosis of pulmonary embolism.
Sensitivity (%) Speciﬁcity (%) Positive predictive value (%) Negative predictive value (%) Accuracy (%)
D-Dimer (>500 ng/ml) 100 80 83.3 100 90
HGF (>500 pg/ml) 97.5 92.5 92.9 97.4 95
Both HGF and D-dimer 100 97.5 97.6 100 98
PE group, pulmonary embolism group; SA group, stable angina group; n, number.
692 A. Dawood et al.The aim of this work is to study the relationship between
hepatocyte growth factor and pulmonary embolism.
In the present study, HGF was measured in all patients and
controls within 24 h of onset of chest pain and before giving
heparin. HGF levels were signiﬁcantly higher in the pulmonary
embolism group compared to the stable angina group and con-
trol group.
Similarly, Hata et al. [11] showed that increased concentra-
tions of circulating HGF were seen in the early stage of pa-
tients with acute pulmonary thromboembolism, but not in
those with stable angina. High concentrations of serum HGF
were speciﬁcally noted in patients with thrombi demonstrated
by angiography, angioscopy, ultrasonography, and tomogra-
phy. These results suggest that an increased concentration of
circulating HGF is a marker of the presence and synthesis of
thrombi in pulmonary arteries.
Also, Li et al. [18] concluded that acute PE was associated
with a signiﬁcant increase in plasma HGF. Moreover, acute
PE was also associated with an enhanced HGF expression in
the lungs, the right ventricle, and the liver.
Nagai et al. [1] found that the ﬁrst increase of the plasma
HGF level was noted 30 min after pulmonary ischemia, and
reached a peak at 12 h. Real-time reverse transcription poly-
merase chain reaction (Real-time RT-PCR) revealed that the
HGF messenger RNA (mRNA) expression in the injured lung
was markedly increased at 1, 6, and 12 h after pulmonary
ischemia. The interleukin-1b (IL-1b) mRNA expression, one
of the inﬂammatory cytokines which induces HGF expression,
was markedly increased at 1 h in the injured left lung. There-
fore, they considered that HGF might be mainly induced by
paracrine mechanisms in pulmonary ischemia.
Two sequence elements, an interleukin-6 (IL-6(response ele-
ment and a potential binding site for nuclear factor IL-6, are
located near the transcription initiation site of the human
HGF gene, and might be involved in the regulation of HGF
gene expression. It has also been reported that inﬂammatory
cytokines such as IL-1b stimulate HGF production. IL-1 is a
multifunctional factor produced by macrophages, monocytes,
neutrophils, vascular endothelial cells, ﬁbroblasts, keratino-
cytes, and Kupffer cells. Among various biological activities,
IL-1 plays an important role as an inﬂammatory cytokine to
mediate acute phase reactions, such as the induction of acute
protein synthesis. IL-1b also stimulates nitric oxide (NO) syn-
thesis in vascular cells. NO, an important regulator of vessel
tone and vascular homeostasis through its effect on platelets
and smooth muscle cell function inhibits platelet adhesion
and aggregation in pulmonary thrombosis. In addition, in-
haled NO is a selective pulmonary vasodilator and effectively
reduces pulmonary hypertension [3,4].
Therefore, it was hypothesized that IL-1b is thought to be
released into the circulation and to act in turn on pulmonary
ischemia with subsequent induction of HGF expression. IL-1b mRNA was rapidly up-regulated in the ischemic lung,
and precedes HGF mRNA, which began at 6 h after the pul-
monary ischemia. Therefore, these studies suggested that IL-
1b might be released in pulmonary ischemia which acts by reg-
ulating HGF gene expression, and is an important regulator of
the vessel. It was shown that the expression of HGF was in-
duced in the early stages of pulmonary ischemia, and was rap-
idly up-regulated compared with in other cardiorespiratory
diseases [3,4].
From the previous data we can concluded that the expres-
sion of HGF was induced in pulmonary ischemia, and may be
a useful biological marker for the early diagnosis.
Another important marker for diagnosis of PE is D-dimer.
D-Dimer, which is fragment speciﬁc to the degradation of ﬁ-
brin, has been reported to be useful in the diagnosis of throm-
bosis. In the present study, D-dimer showed slightly better
sensitivity while, HGF showed markedly better speciﬁcity.
The predictive values of D-dimer in the diagnosis of PE were
as follows: 100% sensitivity and negative predictive value,
80% speciﬁcity, 83.3% positive predictive value and 90%
accuracy, while those of HGF were: 97.5% sensitivity,
97.4% negative predictive value, 92.5% speciﬁcity, 92.9% po-
sitive predictive value and 95% accuracy. When used both D-
dimer and HGF together the values improved to: 100% sensi-
tivity and negative predictive value, 97.5% speciﬁcity, 97.6%
positive predictive value and 98.8% accuracy.
Matsumori et al. showed that increased levels of D-dimer
were found in 6 of 11 patients (55%) with high HGF values,
although patients with increased HGF concentration did not
consistently have elevated D-dimer levels. Because the mecha-
nisms of increase in the concentrations of HGF and D-dimer
may be different, combining the 2 measurements detected cere-
bral thrombosis more reliably on admission (18 of 23 patients)
than either measurement alone [19].
The important question is: how can we use the biological
signiﬁcant elevation of HGF in treatment or adjuvant treat-
ment to the currently used drugs in treatment of PE or as an
adjuvant treatment to the currently used drugs in treatment
of PE?
Yamada et al. [20] concluded that HGF neutralizing treat-
ment with an anti-HGF antibody dramatically reduced DNA
synthesis of alveolar epithelial cells in the reperfused lung
and aggravated lung injury. These ﬁndings suggest that HGF
may play an important role in regeneration of an injured lung
after pulmonary ischemia reperfusion.
Morishita et al. [21] have demonstrated the potential appli-
cation of HGF to treat cardiovascular diseases such as periph-
eral vascular disease, myocardial infarction, pulmonary
embolism and cerebrovascular disease.
Kinoshita et al. [22] reported that heparin rapidly induces
the release of HGF into the circulation, and HGF is a major
factor involved in heparin-induced angiogenesis. Furthermore,
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HGF into the circulation. This new pathway, thrombus forma-
tion-mast cell activation-degranulation-heparin-HGF-angio-
genesis, may be both diagnostically useful and a therapeutic
target in PE.
Drug development using growth factors including HGF re-
mains a challenge, Chung et al. [23] found that HGF, a pleio-
tropic factor regulating development and wound healing, is
secreted as inactive pro-HGF and is converted into active
HGF by coagulation serine proteases. HGF receptor overex-
pression can cause massive venous thrombi, and factor Xa is
reported to release soluble HGF from granulocytes. It is
hypothesized that a hypercoagulable condition, such as dis-
seminated intravascular coagulation (DIC), may increase cir-
culating HGF through active cleavage by coagulation serine
proteases. These ﬁndings suggest that circulating HGF is a po-
tential laboratory marker reﬂecting coagulation activity and
DIC prognosis in non-cancer patients and that HGF may play
a role in a vicious cycle of hypercoagulability [23].
Conclusions
Our observations suggest that the plasma HGF level may be a
useful biological marker of pulmonary ischemia, and a valu-
able tool for early diagnosis of PE. Clariﬁcation of the mech-
anisms, characteristics, and biological signiﬁcance of HGF
elevation is important for clinical use in diagnosing and treat-
ing pulmonary ischemia. The use of both D-dimer and HGF in-
creases the predictive power of both tests when used together.
The clinical signiﬁcance of the role of HGF in the pulmon-
ary embolism opens a new therapeutic area in treating acute
ischemic pulmonary disease that would be able to prolong
the time frame for the application of reperfusion–thrombolytic
therapy.
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